Top

Current Hematologic Malignancy Reports

Published in:

09-02-2024 | Geriatric Assessment

Transplantation and Cellular Therapy for Older Adults—The MSK Approach

Authors: Richard J. Lin, Parastoo B. Dahi, Beatriz Korc-Grodzicki, Armin Shahrokni, Ann A. Jakubowski, Sergio A. Giralt

Published in: Current Hematologic Malignancy Reports | Issue 2/2024

Abstract

Purpose of Review

Hematologic malignances more commonly affect older individuals and often present with advanced, higher risk disease than younger patients. Allogeneic and autologous hematopoietic cell transplantation is well-established treatment modalities with curative potential following either frontline treatments for these diseases or salvage therapy in the relapsed or refractory setting. More recently, novel cellular immunotherapy such as chimeric antigen receptor T-cell therapy has been shown to lead to high response rate and durable remission in many patients with advanced blood cancers.

Recent Findings

Given unique characteristics of older patients, how best to deliver these higher-intensity and time sensitive treatment modalities for them remains challenging. Moreover, their short-term and potential long-term impact on their functional status, cognitive status, and quality of life may be significant considerations for many older patients. All these issues contributed to the lack of access and significant underutilization of these potential curative treatment strategies.

Summary

In this review, we present up to date evidence to support potential benefits of transplantation and cellular therapy for older adults, their steady improving outcomes, and most importantly, highlight the use of geriatric assessment to help select appropriate older patients and optimize them prior to and following transplantation and cellular therapy. We specifically describe our approach at Memorial Sloan Kettering Cancer Center and encouraging early results from its implementation.

Available only for authorised users

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708. (e-pub ahead of print 20220112).CrossRefPubMed

Cronin KA, Scott S, Firth AU, Sung H, Henley SJ, Sherman RL, et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics. Cancer. 2022. https://doi.org/10.1002/cncr.34479. (e-pub ahead of print 20221027).CrossRefPubMed

Dotan E, Walter LC, Browner IS, Clifton K, Cohen HJ, Extermann M, et al. NCCN Guidelines(R) insights: older adult oncology, Version 1.2021. J Natl Compr Canc Netw. 2021;19(9):1006–19. https://doi.org/10.6004/jnccn.2021.0043. (e-pub ahead of print 20210920).CrossRefPubMed

Snowden JA, Sanchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57(8):1217–39. https://doi.org/10.1038/s41409-022-01691-w. (e-pub ahead of print 20220519).CrossRefPubMedPubMedCentral

Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for transplantation and cellular therapy. Biol Blood Marrow Transplant. 2020;26(7):1247–56. https://doi.org/10.1016/j.bbmt.2020.03.002. (e-pub ahead of print 20200309).CrossRefPubMed

Granot N, Storb R. History of hematopoietic cell transplantation: challenges and progress. Haematologica. 2020;105(12):2716–29. https://doi.org/10.3324/haematol.2019.245688. (e-pub ahead of print 20201201).CrossRefPubMedPubMedCentral

Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012;120(20):4256–62. https://doi.org/10.1182/blood-2012-06-436725.CrossRefPubMedPubMedCentral

Auletta JJ, Kou J, Chen M, Bolon Y, Broglie L, Bupp C, et al. Real-world data showing trends and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation: a report from the center for international blood and marrow transplant research. Transplant Cell Ther. 2023;29(6):346.e1–346.e10. https://doi.org/10.1016/j.jtct.2023.03.007

Chabannon C, Kuball J, Bondanza A, Dazzi F, Pedrazzoli P, Toubert, A et al. Hematopoietic stem cell transplantation in its 60s: a platform for cellular therapies. Sci Transl Med. 2018;10(436). https://doi.org/10.1126/scitranslmed.aap9630

10.

Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813–26. https://doi.org/10.1056/NEJMra052638.CrossRefPubMed

11.

Lin RJ, Artz AS. Allogeneic hematopoietic cell transplantation for older patients. Hematol Am Soc Hematol Educ Program. 2021;2021(1):254–63. https://doi.org/10.1182/hematology.2021000257.CrossRef

12.

Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130(9):1156–64. https://doi.org/10.1182/blood-2017-03-772368. (e-pub ahead of print 20170703).CrossRefPubMedPubMedCentral

13.

Rashidi A, Ebadi M, Colditz GA, DiPersio JF. Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2016;22(4):651–7. https://doi.org/10.1016/j.bbmt.2015.10.019. (e-pub ahead of print 20151031).CrossRefPubMed

14.

Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17):1874–83. https://doi.org/10.1001/jama.2011.1558.CrossRefPubMedPubMedCentral

15.•

Maakaron JE, Zhang MJ, Chen K, Abhyankar S, Bhatt VR, Chhabra S, et al. Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. Bone Marrow Transplant. 2022;57(6):911–7. https://doi.org/10.1038/s41409-022-01650-5. e-pub ahead of print 20220402. A comprehensive CIBMTR registry analysis of the impact of age on alloHCT outcomes for AML in CR1 in the modern era.CrossRefPubMedPubMedCentral

16.•

Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, et al. Comparison of patient age groups in transplantation for myelodysplastic syndrome: the medicare coverage with evidence development study. JAMA Oncol. 2020;6(4):486–93. https://doi.org/10.1001/jamaoncol.2019.5140. A comprehensive CIBMTR registry analysis of the impact of age on alloHCT outcomes for MDS in the modern era.CrossRefPubMed

17.

Ringden O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients age >69 years with acute myelogenous leukemia: on behalf of the acute leukemia working party of the european society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2019;25(10):1975–83. https://doi.org/10.1016/j.bbmt.2019.05.037. (e-pub ahead of print 20190607).CrossRefPubMed

18.

Dahi PB, Lee J, Devlin SM, Ruiz J, Maloy M, Rondon-Clavo C, et al. Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. Blood Adv. 2021;5(12):2608–18. https://doi.org/10.1182/bloodadvances.2020004167.CrossRefPubMedPubMedCentral

19.

Chihara D, Izutsu K, Kondo E, Sakai R, Mizuta S, Yokoyama K, et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant. 2014;20(5):684–9. https://doi.org/10.1016/j.bbmt.2014.01.025. (e-pub ahead of print 20140131).CrossRefPubMed

20.

Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20(12):2004–9. https://doi.org/10.1016/j.bbmt.2014.08.019. (e-pub ahead of print 20140828).CrossRefPubMedPubMedCentral

21.

Lin RJ, Lobaugh SM, Pennisi M, Chan HT, Batlevi Y, Ruiz JD, et al. Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma. Haematologica. 2021;106(1):255–8. https://doi.org/10.3324/haematol.2019.243246. (e-pub ahead of print 20210101).CrossRefPubMed

22.•

Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020;135(23):2106–9. https://doi.org/10.1182/blood.2019004162. Outcomes of CAR T therapy in older versus younger patients from ZUMA-1 trial.CrossRefPubMedPubMedCentral

23.

Hurria A, Naylor M, Cohen HJ. Improving the quality of cancer care in an aging population: recommendations from an IOM report. JAMA. 2013;310(17):1795–6. https://doi.org/10.1001/jama.2013.280416.CrossRefPubMed

24.

Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326–47. https://doi.org/10.1200/JCO.2018.78.8687. (e-pub ahead of print 20180521).CrossRefPubMedPubMedCentral

25.

Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603. https://doi.org/10.1200/JCO.2013.54.8347.CrossRefPubMedPubMedCentral

26.••

DuMontier C, Loh KP, Bain PA, Silliman RA, Hshieh T, Abel GA, et al. Defining undertreatment and overtreatment in older adults with cancer: a scoping literature review. J Clin Oncol. 2020;38(22):2558–69. https://doi.org/10.1200/JCO.19.02809. e-pub ahead of print 20200406. A conceptual understanding of how geriatric assessment and management could improve modern cancer care.CrossRefPubMedPubMedCentral

27.•

Flannelly C, Tan BE, Tan JL, McHugh CM, Sanapala C, Lagu T, et al. Barriers to hematopoietic cell transplantation for adults in the united states: a systematic review with a focus on age. Biol Blood Marrow Transplant. 2020;26(12):2335–45. https://doi.org/10.1016/j.bbmt.2020.09.013. >e-pub ahead of print 20200920. Chronologic age impacts on alloHCT referrals for older patients.CrossRefPubMedPubMedCentral

28.

Meyer C, Mau LW, Murphy EA, Denzen EM, Hayes E, Haven D, et al. Addressing knowledge gaps in acute myeloid leukemia to improve referral for hematopoietic cell transplantation consultation. J Natl Compr Canc Netw. 2019;17(12):1473–81. https://doi.org/10.6004/jnccn.2019.7327.CrossRefPubMed

29.

Appelbaum FR. Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia. Best Pract Res Clin Haematol. 2021;34(4):101320. https://doi.org/10.1016/j.beha.2021.101320. (e-pub ahead of print 20211022).CrossRefPubMed

30.

Vasu S, Kohlschmidt J, Mrozek K, Eisfeld AK, Nicolet D, Sterling LJ, et al. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018;2(13):1645–50. https://doi.org/10.1182/bloodadvances.2017015222. (e-pub ahead of print 2018/07/12).CrossRefPubMedPubMedCentral

31.

Pulte D, Jansen L, Castro FA, Brenner H. Changes in the survival of older patients with hematologic malignancies in the early 21st century. Cancer. 2016;122(13):2031–40. https://doi.org/10.1002/cncr.30003. (e-pub ahead of print 2016/05/11).CrossRefPubMed

32.••

Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019;33(11):2599–609. https://doi.org/10.1038/s41375-019-0477-x. e-pub ahead of print 20190509. A non-randomized, but elegant analysis that demonstrated that older patients with AML in CR1 could benefit from alloHCT, albeit with heightened early mortality.CrossRefPubMedPubMedCentral

33.

Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ et al. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol 2015;2(10): https://doi.org/10.1016/S2352-3026(15)00148-9 (e-pub ahead of print 2015/12/22)

34.•

Mishra A, Preussler JM, Bhatt VR, Bredeson C, Chhabra S, D’Souza A, et al. Breaking the age barrier: physicians’ perceptions of candidacy for allogeneic hematopoietic cell transplantation in older adults. Transplant Cell Ther. 2021;27(7):617 e611-617 e617. https://doi.org/10.1016/j.jtct.2021.03.028. e-pub ahead of print 20210406. A large ASTCT survey of physician attitude and barriers on transplanting older patients.CrossRef

35.••

Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50–75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39(30):3328–39. https://doi.org/10.1200/JCO.20.03380. e-pub ahead of print 20210609. The landmark BMT CTN study of biological assignment of donor versus no-donor treatment demonstrating survival improvement with alloHCT for older, higher risk MDS patients.CrossRefPubMedPubMedCentral

36.

Cusatis R, Martens MJ, Nakamura R, Cutler CS, Saber W, Lee SJ, et al. Health-related quality of life in reduced intensity hematopoietic cell transplantation based on donor availability in patients aged 50–75 with advanced myelodysplastic syndrome: BMT CTN 1102. Am J Hematol. 2022. https://doi.org/10.1002/ajh.26768. (e-pub ahead of print 20221017).CrossRefPubMedPubMedCentral

37.

Warlick ED, Ustun C, Andreescu A, Bonagura AF, Brunner A, Chandra AB, et al. Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: challenges and opportunities in implementation. Cancer. 2021;127(23):4339–47. https://doi.org/10.1002/cncr.33826. (e-pub ahead of print 20210810).CrossRefPubMed

38.

Getta BM, Kishtagari A, Hilden P, Tallman MS, Maloy M, Gonzales P, et al. Allogeneic hematopoietic stem cell transplantation is underutilized in older patients with myelodysplastic syndromes. Biol Blood Marrow Transplant. 2017;23(7):1078–86. https://doi.org/10.1016/j.bbmt.2017.03.020. (e-pub ahead of print 20170320).CrossRefPubMedPubMedCentral

39.

Kantarjian H, Short NJ, DiNardo C, Stein EM, Daver N, Perl AE, et al. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematol. 2021;8(12):e922–33. https://doi.org/10.1016/S2352-3026(21)00270-2. (e-pub ahead of print 20211020).CrossRefPubMedPubMedCentral

40.

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–29. https://doi.org/10.1056/NEJMoa2012971.CrossRefPubMed

41.

Uy GL, Newell LF, Lin TL, Goldberg SL, Wieduwilt MJ, Ryan RJ, et al. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv. 2022;6(17):4989–93. https://doi.org/10.1182/bloodadvances.2021006468.CrossRefPubMedPubMedCentral

42.

Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, et al. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplant. 2022;57(2):160–6. https://doi.org/10.1038/s41409-021-01476-7. (e-pub ahead of print 20211013).CrossRefPubMed

43.

Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, et al. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from cancer and leukemia group B 100103 (alliance for clinical trials in oncology)/blood and marrow transplant clinical trial network 0502. J Clin Oncol. 2015;33(35):4167–75. https://doi.org/10.1200/JCO.2015.62.7273. (e-pub ahead of print 20151102).CrossRefPubMedPubMedCentral

44.

Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89(12):4531–6 (e-pub ahead of print 1997/06/15).CrossRefPubMed

45.

Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157–67. https://doi.org/10.1016/S2352-3026(19)30256-X.CrossRefPubMed

46.

Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC et al. National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide. J Clin Oncol 2021;JCO2003502. https://doi.org/10.1200/JCO.20.03502 (e-pub ahead of print 2021/04/28)

47.

Griffin JM, Healy FM, Dahal LN, Floisand Y, Woolley JF. Worked to the bone: antibody-based conditioning as the future of transplant biology. J Hematol Oncol. 2022;15(1):65. https://doi.org/10.1186/s13045-022-01284-6. (e-pub ahead of print 20220519).CrossRefPubMedPubMedCentral

48.

Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Remenyi P, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7(1):e28–39. https://doi.org/10.1016/S2352-3026(19)30157-7. (e-pub ahead of print 20191009).CrossRefPubMed

49.

Murdock HM, Kim HT, Denlinger N, Vachhani P, Hambley B, Manning BS, et al. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML. Blood. 2022;139(24):3546–57. https://doi.org/10.1182/blood.2021014520.CrossRefPubMedPubMedCentral

50.

Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38(12):1273–83. https://doi.org/10.1200/JCO.19.03011. (e-pub ahead of print 2019/12/21).CrossRefPubMed

51.

Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, et al. Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation-a systematic review and meta-analysis. Transplant Cell Ther. 2021;27(12):997 e991-997 e911. https://doi.org/10.1016/j.jtct.2021.09.005. (e-pub ahead of print 20210920).CrossRef

52.••

Sorror ML, Gooley TA, Storer BE, Gerds AT, Sekeres MA, Medeiros BC, et al. An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients. Blood. 2022. https://doi.org/10.1182/blood.2022016916. e-pub ahead of print 20221019. A recent multicenter observational study demonstrating that the benefits of alloHCT is restricted to selected older individuals without significant comorbidities or functional impairments.CrossRefPubMedPubMedCentral

53.

Rosko AE, Cordoba R, Abel G, Artz A, Loh KP, Klepin HD. Advances in management for older adults with hematologic malignancies. J Clin Oncol. 2021;39(19):2102–14. https://doi.org/10.1200/JCO.21.00242. (e-pub ahead of print 20210527).CrossRefPubMedPubMedCentral

54.

Kuchel GA. Frailty and resilience as outcome measures in clinical trials and geriatric care: are we getting any closer? J Am Geriatr Soc. 2018;66(8):1451–4. https://doi.org/10.1111/jgs.15441. (e-pub ahead of print 20180809).CrossRefPubMedPubMedCentral

55.

Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99(8):1373–9. https://doi.org/10.3324/haematol.2014.103655. (e-pub ahead of print 2014/05/13).CrossRefPubMedPubMedCentral

56.

Muffly LS, Boulukos M, Swanson K, Kocherginsky M, Cerro PD, Schroeder L, et al. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant. 2013;19(3):429–34. https://doi.org/10.1016/j.bbmt.2012.11.006. (e-pub ahead of print 2012/11/20).CrossRefPubMed

57.

Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, et al. Limitation in patient-reported function is associated with inferior survival in older adults undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(6):1218–24. https://doi.org/10.1016/j.bbmt.2019.01.028. (e-pub ahead of print 20190130).CrossRefPubMed

58.•

Kennedy VE, Olin RL. Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care. Lancet Haematol. 2021;8(11):e853–61. https://doi.org/10.1016/S2352-3026(21)00231-3. e-pub ahead of print 20211005 .An uptodate review on transplant consideration in older adults.CrossRefPubMed

59.••

Derman BA, Kordas K, Ridgeway J, Chow S, Dale W, Lee SM, et al. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019;3(22):3488–98. https://doi.org/10.1182/bloodadvances.2019000790. e-pub ahead of print 2019/11/15. The first study demonstrating the impact of GA-guided management for transplant patients.CrossRefPubMedPubMedCentral

60.

Lew MV, Ren Y, Lowder YP, Siamakpour-Reihani S, Ramalingam S, Romero KM, et al. Geriatric assessment reveals actionable impairments in hematopoietic stem cell transplantation candidates age 18 to 80 years. Transplant Cell Ther. 2022;28(8):498 e491-498 e499. https://doi.org/10.1016/j.jtct.2022.05.018. (e-pub ahead of print 20220517).CrossRef

61.

Shahrokni A, Alexander K, Wildes TM, Puts MTE. Preventing treatment-related functional decline: strategies to maximize resilience. Am Soc Clin Oncol Educ Book. 2018;38:415–31. https://doi.org/10.1200/EDBK_200427.CrossRefPubMed

62.

Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, et al. Patterns and predictors of functional decline after allogeneic hematopoietic cell transplantation in older adults. Transplant Cell Ther. 2022;28(6):309 e301-309 e309. https://doi.org/10.1016/j.jtct.2022.02.022. (e-pub ahead of print 20220303).CrossRef

63.

Lin RJ, Baser RE, Elko TA, Korc-Grodzicki B, Shahrokni A, Maloy MA, et al. Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021;56(1):289–92. https://doi.org/10.1038/s41409-020-01001-2. (e-pub ahead of print 2020/07/23).CrossRefPubMed

64.

Lin RJ, Hilden PD, Elko TA, Dahi PB, Shahrokni A, Jakubowski AA, et al. Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults. Blood Adv. 2019;3(1):12–20. https://doi.org/10.1182/bloodadvances.2018028241. (e-pub ahead of print 2019/01/05).CrossRefPubMedPubMedCentral

65.

Shah GL, Scordo M, Kosuri S, Herrera DA, Cho C, Devlin SM, et al. Impact of toxicity on survival for older adult patients after CD34(+) selected allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(1):142–9. https://doi.org/10.1016/j.bbmt.2017.08.040. (e-pub ahead of print 20170922).CrossRefPubMed

66.

Jakubowski AA, Petrlik E, Maloy M, Hilden P, Papadopoulos E, Young JW, et al. T cell depletion as an alternative approach for patients 55 years or older undergoing allogeneic stem cell transplantation as curative therapy for hematologic malignancies. Biol Blood Marrow Transplant. 2017;23(10):1685–94. https://doi.org/10.1016/j.bbmt.2017.06.024. (e-pub ahead of print 20170719).CrossRefPubMedPubMedCentral

67.

Shahrokni A, Tin A, Downey RJ, Strong V, Mahmoudzadeh S, Boparai MK, et al. Electronic rapid fitness assessment: a novel tool for preoperative evaluation of the geriatric oncology patient. J Natl Compr Canc Netw. 2017;15(2):172–9. https://doi.org/10.6004/jnccn.2017.0018.CrossRefPubMedPubMedCentral

68.

Shahrokni A, Tin AL, Sarraf S, Alexander K, Sun S, Kim SJ, et al. Association of geriatric comanagement and 90-day postoperative mortality among patients aged 75 years and older with cancer. JAMA Netw Open. 2020;3(8):e209265. https://doi.org/10.1001/jamanetworkopen.2020.9265. (e-pub ahead of print 20200803).CrossRefPubMedPubMedCentral

69.

Lin RJ, Dahi PB, Shahrokni A, Sarraf S, Korc-Grodzicki B, Devlin SM, et al. Feasibility of a patient-reported, electronic geriatric assessment tool in hematopoietic cell transplantation - a single institution pilot study. Leuk Lymphoma. 2019;60(13):3308–11. https://doi.org/10.1080/10428194.2019.1630621. (e-pub ahead of print 20190621).CrossRefPubMedPubMedCentral

70.

Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM. Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 2016;7(5):346–53. https://doi.org/10.1016/j.jgo.2016.07.010.CrossRefPubMedPubMedCentral

71.

Deschler B, Ihorst G, Schnitzler S, Bertz H, Finke J. Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis. Bone Marrow Transplant. 2018;53(5):565–75. https://doi.org/10.1038/s41409-017-0021-4. (e-pub ahead of print 20180112).CrossRefPubMed

72.

Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, et al. Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2020;26(1):189–96. https://doi.org/10.1016/j.bbmt.2019.08.022. (e-pub ahead of print 20190905).CrossRefPubMed

73.

Pamukcuoglu M, Bhatia S, Weisdorf DJ, DeFor TE, Ustun C, Nayar M, et al. Hematopoietic cell transplant-related toxicities and mortality in frail recipients. Biol Blood Marrow Transplant. 2019;25(12):2454–60. https://doi.org/10.1016/j.bbmt.2019.07.030. (e-pub ahead of print 2019/08/09).CrossRefPubMedPubMedCentral

74.

Salas MQ, Atenafu EG, Bascom O, Wilson L, Lam W, Law AD, et al. Pilot prospective study of frailty and functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021;56(1):60–9. https://doi.org/10.1038/s41409-020-0979-1. (e-pub ahead of print 2020/07/02).CrossRefPubMed

75.

Olin RL, Fretham C, Pasquini MC, Arora M, Bhatt VR, Derman B, et al. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020;4(12):2810–20. https://doi.org/10.1182/bloodadvances.2020001719.CrossRefPubMedPubMedCentral

76.

Polverelli N, Tura P, Battipaglia G, Malagola M, Bernardi S, Gandolfi L, et al. Multidimensional geriatric assessment for elderly hematological patients (>/=60 years) submitted to allogeneic stem cell transplantation A French-Italian 10-year experience on 228 patients. Bone Marrow Transplant. 2020;55(12):2224–33. https://doi.org/10.1038/s41409-020-0934-1. (e-pub ahead of print 2020/05/14).CrossRefPubMed

77.

Lin RJ, Elko TA, Devlin SM, Shahrokni A, Jakubowski AA, Dahi PB, et al. Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. Bone Marrow Transplant. 2020;55(1):157–64. https://doi.org/10.1038/s41409-019-0654-6. (e-pub ahead of print 2019/09/01).CrossRefPubMed

78.

Bhargava D, Arora M, DeFor TE, Brunstein CG, Thyagarajan B, El Jurdi N, et al. Use of potentially inappropriate medications in older allogeneic hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2020;26(12):2329–34. https://doi.org/10.1016/j.bbmt.2020.08.031. (e-pub ahead of print 2020/09/13).CrossRefPubMedPubMedCentral

79.

Sugidono M, Lo M, Young R, Rosario K, Jung Y, Huang CY, et al. Impact of polypharmacy prior to allogeneic hematopoietic stem cell transplantation in older adults. Transplant Cell Ther. 2021;27(4):344 e341-344 e345. https://doi.org/10.1016/j.jtct.2021.01.001. (e-pub ahead of print 2021/04/11).CrossRef

80.

Kennedy VE, Huang CY, Kaplan LD, Andreadis C, Ai WZ, Olin RL. Geriatric assessment in adults age 50 years and older undergoing autologous hematopoietic cell transplantation for lymphoma. J Geriatr Oncol. 2022;13(5):644–7. https://doi.org/10.1016/j.jgo.2022.02.016. (e-pub ahead of print 20220304).CrossRefPubMed

Title: Transplantation and Cellular Therapy for Older Adults—The MSK Approach
Authors: Richard J. Lin
Parastoo B. Dahi
Beatriz Korc-Grodzicki
Armin Shahrokni
Ann A. Jakubowski
Sergio A. Giralt
Publication date: 09-02-2024
Publisher: Springer US
Keyword: Geriatric Assessment
Published in: Current Hematologic Malignancy Reports / Issue 2/2024
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-024-00725-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2024

Frontline Therapy of CLL—Changing Treatment Paradigms

How Do We Manage Chronic Lymphocytic Leukemia in India

Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations

Novel therapies for Richter’s transformation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials